JP2019513804A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513804A5 JP2019513804A5 JP2018554572A JP2018554572A JP2019513804A5 JP 2019513804 A5 JP2019513804 A5 JP 2019513804A5 JP 2018554572 A JP2018554572 A JP 2018554572A JP 2018554572 A JP2018554572 A JP 2018554572A JP 2019513804 A5 JP2019513804 A5 JP 2019513804A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- cycloalkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 claims 31
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 8
- 125000006417 CH Chemical group [H]C* 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- -1 2,4-difluorophenoxy Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000026278 immune system disease Diseases 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 230000001613 neoplastic effect Effects 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- QOQREUBQBHJFNS-CQSZACIVSA-N (2R)-N-[2-(2-fluoro-6-methylphenoxy)-6-(1-methyl-6-oxopyridin-3-yl)pyrimidin-4-yl]butane-2-sulfonamide Chemical compound FC1=C(OC2=NC(=CC(=N2)NS(=O)(=O)[C@H](C)CC)C2=CN(C(C=C2)=O)C)C(=CC=C1)C QOQREUBQBHJFNS-CQSZACIVSA-N 0.000 claims 1
- QOQREUBQBHJFNS-AWEZNQCLSA-N (2S)-N-[2-(2-fluoro-6-methylphenoxy)-6-(1-methyl-6-oxopyridin-3-yl)pyrimidin-4-yl]butane-2-sulfonamide Chemical compound FC1=C(OC2=NC(=CC(=N2)NS(=O)(=O)[C@@H](C)CC)C2=CN(C(C=C2)=O)C)C(=CC=C1)C QOQREUBQBHJFNS-AWEZNQCLSA-N 0.000 claims 1
- FLNHKHUSIINDGR-UHFFFAOYSA-N 3,3,3-trifluoro-N-[2-(2-fluoro-6-methylphenoxy)-6-(1-methyl-6-oxopyridin-3-yl)pyrimidin-4-yl]propane-1-sulfonamide Chemical compound FC1=C(OC2=NC(=CC(=N2)NS(=O)(=O)CCC(F)(F)F)C2=CN(C(C=C2)=O)C)C(=CC=C1)C FLNHKHUSIINDGR-UHFFFAOYSA-N 0.000 claims 1
- BPLBOVPXBOLUTH-UHFFFAOYSA-N 4,4,4-trifluoro-N-[2-(2-fluoro-6-methylphenoxy)-6-(1-methyl-6-oxopyridin-3-yl)pyrimidin-4-yl]butane-1-sulfonamide Chemical compound FC1=C(OC2=NC(=CC(=N2)NS(=O)(=O)CCCC(F)(F)F)C2=CN(C(C=C2)=O)C)C(=CC=C1)C BPLBOVPXBOLUTH-UHFFFAOYSA-N 0.000 claims 1
- 125000006416 CBr Chemical group BrC* 0.000 claims 1
- 125000006414 CCl Chemical group ClC* 0.000 claims 1
- 125000006415 CF Chemical group FC* 0.000 claims 1
- NJQHAFKVBSGXRC-UHFFFAOYSA-N N-[2-(2,4-dichloro-6-methylphenoxy)-6-(1,5-dimethyl-6-oxopyridin-3-yl)pyrimidin-4-yl]propane-2-sulfonamide Chemical compound ClC1=C(OC2=NC(=CC(=N2)NS(=O)(=O)C(C)C)C2=CN(C(C(=C2)C)=O)C)C(=CC(=C1)Cl)C NJQHAFKVBSGXRC-UHFFFAOYSA-N 0.000 claims 1
- FAVDKQWNPLKKFB-UHFFFAOYSA-N N-[2-(2-chloro-6-methylphenoxy)-6-(1,5-dimethyl-6-oxopyridin-3-yl)pyrimidin-4-yl]butane-1-sulfonamide Chemical compound ClC1=C(OC2=NC(=CC(=N2)NS(=O)(=O)CCCC)C2=CN(C(C(=C2)C)=O)C)C(=CC=C1)C FAVDKQWNPLKKFB-UHFFFAOYSA-N 0.000 claims 1
- KIUXMESFQFPSQB-UHFFFAOYSA-N N-[2-(2-fluoro-6-methylphenoxy)-6-(1-methyl-6-oxopyridin-3-yl)pyrimidin-4-yl]butane-1-sulfonamide Chemical compound FC1=C(OC2=NC(=CC(=N2)NS(=O)(=O)CCCC)C2=CN(C(C=C2)=O)C)C(=CC=C1)C KIUXMESFQFPSQB-UHFFFAOYSA-N 0.000 claims 1
- 210000000068 Th17 cell Anatomy 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022013404A JP2022064967A (ja) | 2016-04-18 | 2022-01-31 | 治療用化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662324279P | 2016-04-18 | 2016-04-18 | |
| US62/324,279 | 2016-04-18 | ||
| PCT/US2017/027815 WO2017184462A1 (en) | 2016-04-18 | 2017-04-14 | Therapeutic compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022013404A Division JP2022064967A (ja) | 2016-04-18 | 2022-01-31 | 治療用化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019513804A JP2019513804A (ja) | 2019-05-30 |
| JP2019513804A5 true JP2019513804A5 (enExample) | 2020-05-21 |
Family
ID=60039979
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554572A Pending JP2019513804A (ja) | 2016-04-18 | 2017-04-14 | 治療用化合物 |
| JP2022013404A Pending JP2022064967A (ja) | 2016-04-18 | 2022-01-31 | 治療用化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022013404A Pending JP2022064967A (ja) | 2016-04-18 | 2022-01-31 | 治療用化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10202360B2 (enExample) |
| EP (1) | EP3445750A4 (enExample) |
| JP (2) | JP2019513804A (enExample) |
| AR (1) | AR108223A1 (enExample) |
| AU (1) | AU2017252276A1 (enExample) |
| TW (1) | TW201739744A (enExample) |
| WO (1) | WO2017184462A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202332436A (zh) | 2017-04-18 | 2023-08-16 | 美商塞爾基因定量細胞研究公司 | 治療用化合物 |
| CN110016014B (zh) * | 2018-01-08 | 2023-02-17 | 中国科学院上海药物研究所 | Ezh2抑制剂及其制备和抗肿瘤治疗中的应用 |
| BR112020019824A2 (pt) | 2018-03-29 | 2021-01-05 | Board Of Regents, The University Of Texas System | Composto de fórmula estrutural i ou um sal do mesmo, composição farmacêutica, método de inibição de cbp, método de inibição de p300, método de tratamento de uma doença mediada por cbp, método de tratamento de uma doença mediada por p300 e método para alcançar um efeito em um paciente |
| WO2019195846A1 (en) | 2018-04-06 | 2019-10-10 | Board Of Regents, The University Of Texas System | Imidazopiperazinone inhibitors of transcription activating proteins |
| JP7465945B2 (ja) | 2019-07-02 | 2024-04-11 | ニューベイション・バイオ・インコーポレイテッド | Ｂｅｔ阻害剤としてのヘテロ環式化合物 |
| EP4143166A4 (en) * | 2020-04-29 | 2024-10-30 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
| KR20230057341A (ko) | 2020-07-02 | 2023-04-28 | 인사이트 코포레이션 | Jak2 v617f 억제제로서 삼환계 우레아 화합물 |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| AU2021355480B2 (en) | 2020-10-02 | 2026-03-05 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| EP4221708A4 (en) | 2020-10-02 | 2024-11-06 | Board of Regents, The University of Texas System | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION-ACTIVATING PROTEINS |
| CN112225738B (zh) * | 2020-12-18 | 2021-04-13 | 北京鑫开元医药科技有限公司 | 作为tlr8激动剂的化合物、其制备方法、组合物及其用途 |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
| CN115703760B (zh) * | 2021-08-11 | 2024-05-31 | 山东大学 | 2,4-二取代嘧啶类细胞周期蛋白依赖性激酶酶抑制剂及其制备方法和应用 |
| PT4426434T (pt) | 2021-11-02 | 2025-11-24 | Flare Therapeutics Inc | Agonistas inversos de pparg e suas utilizações |
| PE20251706A1 (es) | 2022-03-17 | 2025-07-02 | Incyte Corp | Compuestos de urea triciclica como inhibidores de v617f de jak2 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2011970A1 (en) | 1970-03-13 | 1971-11-18 | CH. Boehringer Sohn, 6507 Ingelheim | Imidazo-(1, 2-a)- pyrimidines prepn |
| US3635667A (en) | 1970-07-23 | 1972-01-18 | Fmc Corp | Drycleaning with hydrogen peroxide |
| BE786028A (fr) | 1971-07-08 | 1973-01-08 | Boehringer Sohn Ingelheim | 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer |
| DE2356005A1 (de) | 1973-11-09 | 1975-05-22 | Boehringer Sohn Ingelheim | Neue 7-amino-imidazo eckige klammer auf 1,2-a eckige klammer zu pyrimidine, diese enthaltende arzneimittel sowie verfahren zu deren herstellung |
| AU577105B2 (en) | 1985-04-02 | 1988-09-15 | T.P.O. :Pharmachim: | Acylaminic penicillin derivatives |
| US6117940A (en) | 1997-10-17 | 2000-09-12 | Mjalli; Adnan M. M. | Amino-ketone solid support templates |
| EP1556381B1 (en) | 2002-09-26 | 2008-02-20 | Pfizer Limited | Pyrazole amides for treating hiv infections |
| JP2005089352A (ja) | 2003-09-16 | 2005-04-07 | Kissei Pharmaceut Co Ltd | 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| WO2005030791A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Isoquinolinone potassium channel inhibitors |
| KR100703068B1 (ko) | 2003-12-30 | 2007-04-05 | 에스케이케미칼주식회사 | 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물 |
| CA2562126A1 (en) | 2004-04-01 | 2005-10-13 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| KR100781704B1 (ko) | 2005-04-20 | 2007-12-03 | 에스케이케미칼주식회사 | 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물 |
| US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
| PT1910333E (pt) | 2005-07-26 | 2013-08-01 | Sanofi Sa | Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase |
| HRP20110839T1 (hr) | 2005-07-26 | 2011-12-31 | Sanofi | Derivati cikloheksaminizokinolona kao inhibitori rho-kinaze |
| US20070099911A1 (en) | 2005-10-28 | 2007-05-03 | Wyeth | Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands |
| WO2008039882A1 (en) * | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
| JP5405314B2 (ja) | 2006-12-27 | 2014-02-05 | サノフイ | シクロアルキルアミン置換イソキノロン誘導体 |
| RU2468011C2 (ru) | 2006-12-27 | 2012-11-27 | Санофи-Авентис | Замещенные циклоалкиламином производные изохинолина и изохинолинона |
| MY150746A (en) | 2006-12-27 | 2014-02-28 | Sanofi Aventis | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase |
| TW200906825A (en) * | 2007-05-30 | 2009-02-16 | Scripps Research Inst | Inhibitors of protein kinases |
| US20090054434A1 (en) | 2007-08-23 | 2009-02-26 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
| CA2712897A1 (en) | 2008-01-30 | 2009-08-06 | Pharmacopeia, Inc. | Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands |
| JP5433691B2 (ja) | 2008-06-25 | 2014-03-05 | ブリストル−マイヤーズ スクイブ カンパニー | Ｈｉｖ結合阻害剤としてのジケトピペリジン誘導体 |
| EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| EP2485731B1 (en) | 2009-10-06 | 2016-05-11 | Millennium Pharmaceuticals, Inc. | Heterocyclic compounds useful as pdk1 inhibitors |
| SG186855A1 (en) | 2010-06-28 | 2013-02-28 | Merck Patent Gmbh | 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer |
| JPWO2012020786A1 (ja) * | 2010-08-11 | 2013-10-28 | 日本新薬株式会社 | 医薬組成物 |
| US9481670B2 (en) * | 2011-01-25 | 2016-11-01 | Sphaera Pharma Pte. Ltd. | Triazine compounds |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| EP2773641B1 (en) | 2011-10-31 | 2017-09-27 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
| CN103183675A (zh) | 2011-12-27 | 2013-07-03 | 山东轩竹医药科技有限公司 | 磷酸二酯酶-4抑制剂 |
| AU2013268400B2 (en) * | 2012-05-30 | 2017-07-13 | Nippon Shinyaku Co., Ltd. | Aromatic heterocyclic derivative and pharmaceutical |
| WO2014096965A2 (en) * | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| KR20150126696A (ko) * | 2013-03-12 | 2015-11-12 | 애브비 인코포레이티드 | 디하이드로-피롤로피리디논 브로모도메인 억제제 |
| KR20150128842A (ko) * | 2013-03-14 | 2015-11-18 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 브로모도메인 억제제로서의 퓨로피리딘 |
| BR112015027381A8 (pt) * | 2013-05-01 | 2018-01-30 | Hoffmann La Roche | pirimidinas substituídas por heterocicloalquila ligadas ao c e seus usos |
| AU2014337064B2 (en) * | 2013-10-18 | 2019-03-14 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
| LT3092227T (lt) * | 2014-01-09 | 2018-08-10 | Orion Corporation | Bicikliniai heterocikliniai dariniai kaip bromodomeno inhibitoriai |
| RU2016151390A (ru) * | 2014-06-04 | 2018-07-17 | Томас Хелледайс Стифтелсе Фёр Медисинск Форскнинг | Ингибиторы мтн1 для лечения воспалительных и аутоиммунных заболеваний |
| AU2017300336B2 (en) * | 2016-07-18 | 2021-03-11 | National Institute Of Biological Sciences, Beijing | Apoptosis inhibitors |
-
2017
- 2017-04-14 WO PCT/US2017/027815 patent/WO2017184462A1/en not_active Ceased
- 2017-04-14 AU AU2017252276A patent/AU2017252276A1/en not_active Abandoned
- 2017-04-14 JP JP2018554572A patent/JP2019513804A/ja active Pending
- 2017-04-14 EP EP17786389.1A patent/EP3445750A4/en not_active Withdrawn
- 2017-04-17 US US15/488,674 patent/US10202360B2/en active Active
- 2017-04-18 TW TW106112891A patent/TW201739744A/zh unknown
- 2017-04-18 AR ARP170100985A patent/AR108223A1/es unknown
-
2022
- 2022-01-31 JP JP2022013404A patent/JP2022064967A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513804A5 (enExample) | ||
| RU2016134947A (ru) | Производные диаминопиримидин бензолсульфона и их применение | |
| JP2017504653A5 (enExample) | ||
| JP2016531113A5 (enExample) | ||
| JP2016506387A5 (enExample) | ||
| JP2012255002A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2017533968A5 (enExample) | ||
| JP2013543896A5 (enExample) | ||
| JP2017523225A5 (enExample) | ||
| RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
| JP2014523901A5 (enExample) | ||
| JP2017504651A5 (enExample) | ||
| JP2016534134A5 (enExample) | ||
| JP2015503620A5 (enExample) | ||
| JP2017504576A5 (enExample) | ||
| JP2019531279A5 (enExample) | ||
| JP2011510080A5 (enExample) | ||
| JP2014502979A5 (enExample) | ||
| JP2016531126A5 (enExample) | ||
| JP2017516796A5 (enExample) | ||
| JP2020537671A5 (enExample) | ||
| JP2020530848A5 (enExample) | ||
| RU2017145928A (ru) | МОДУЛЯТОРЫ ROR ГАММА (RORγ) | |
| JP2004532894A5 (enExample) |